Horizon Technology Finance Corporation: Q1 2024 Form 10-Q Summary
Business context and reporting period
Horizon Technology Finance Corporation is an externally managed, non-diversified business development company and regulated investment company. It provides primarily secured venture loans and related warrants to development-stage companies in life science, technology, healthcare information and services, and sustainability industries. The filing covers the three months ended March 31, 2024; financial statements are unaudited.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 or prior period |
|---|---|---|
| Total investment income | $26.1 million | $28.0 million |
| Net investment income | $12.6 million; $0.38 per share | $13.0 million; $0.46 per share |
| Net increase in net assets from operations | $8.7 million; $0.26 per share | $5.3 million; $0.19 per share |
| Net realized gain on investments | $0.01 million | $0.2 million loss |
| Net unrealized depreciation | $4.0 million | $7.5 million |
| Operating cash flow | $4.0 million | $12.7 million |
| Fair value of investments | $711.1 million | $709.1 million at December 31, 2023 |
| Net assets | $332.1 million | $324.0 million at December 31, 2023 |
| NAV per share | $9.64 | $9.71 at December 31, 2023 |
| Borrowings, net | $452.5 million | $462.2 million at December 31, 2023 |
Total investment income decreased 6.8% year over year, principally because average earning debt investments declined 7.2%, partly offset by higher Prime-based rates. Net investment income represented approximately 48% of total investment income, while the net increase in assets from operations represented approximately 33%.
Debt investments had a fair value of $670.8 million, or 94.3% of the portfolio. Warrants had a fair value of $23.9 million, other investments $9.2 million, and equity investments $7.2 million. Approximately 87.0% of debt investments at fair value consisted of senior term loans. The dollar-weighted annualized yield was 15.6% on debt investments and 14.7% on all investments, compared with 16.3% and 15.5%, respectively, in Q1 2023.
Cash, money market funds, and restricted money market funds totaled $71.3 million at March 31, 2024, including $68.8 million of unrestricted cash and money market funds and $2.5 million of restricted funds. Asset coverage for borrowings was 173%, compared with the statutory minimum of 150%.
Material changes versus the prior comparable period
- Total expenses declined 11.4% to $13.1 million. Interest expense increased 14.6% to $8.2 million because of higher average borrowings and higher funding costs.
- Performance-based incentive fee expense fell 90.1% to $0.3 million. The incentive fee cap and deferral mechanism reduced current-quarter expense by $2.3 million.
- Net investment income per share declined from $0.46 to $0.38, despite lower total expenses, reflecting lower investment income and a larger share count.
- Net increase in net assets from operations rose to $8.7 million because unrealized depreciation declined to $4.0 million from $7.5 million.
- The company issued 1.05 million common shares under its 2023 at-the-market program for approximately $12.0 million of net proceeds, compared with 605,848 shares and $7.2 million in Q1 2023.
- Borrowings declined by $9.7 million, primarily because the company repaid $10.0 million under the Key Facility. Total unused borrowing commitments increased to $159.0 million from $149.0 million, although availability remained subject to facility terms and advance rates.
- Portfolio fair value increased modestly, while the portfolio mix shifted toward medical devices and sustainability investments and away from software and other sustainability investments.
Guidance, outlook, management commentary, risks and unusual items
The filing does not provide formal earnings, investment-originations, or dividend guidance. Management states that current cash, operating cash generation, and available credit facilities are expected to be sufficient to meet working-capital and capital-commitment requirements for at least the next 12 months. Management also expects to raise additional equity and debt capital opportunistically, subject to market conditions and regulatory limits.
- Four debt investments were on non-accrual status at March 31, 2024, with aggregate cost of $96.0 million and fair value of $51.0 million. No interest income was recognized from non-accrual debt investments during the quarter.
- Debt investments rated the lowest internal credit grade represented $51.0 million of fair value, or 7.6% of debt investments, compared with 4.1% at December 31, 2023. The weighted-average internal credit rating remained 3.1.
- Nexii Building Solutions and affiliates entered Canadian creditor-protection proceedings in January 2024. The company’s Nexii loans had substantially reduced fair value relative to cost and were on non-accrual status.
- PIK interest represented 5.3% of total investment income and ETP income not received in cash represented 6.8%. These items increase reported income without corresponding current-period cash receipts.
- The company had $168.2 million of unfunded lending commitments, including $131.2 million due within one year. These commitments are generally conditional and may expire without being drawn.
- The company’s $13.1 million contingent incentive-fee deferral may become payable over periods extending through March 2027, subject to the applicable fee-cap mechanism.
- Approximately 94% of outstanding debt-investment principal bore floating rates. Management estimates that a 100-basis-point rate increase would increase annual net assets by approximately $5.1 million, while a 100-basis-point decrease would reduce annual net assets by approximately $3.6 million, before incentive-fee effects.
- Key risks include portfolio-company defaults, valuation uncertainty for Level 3 investments, interest-rate and refinancing risk, dependence on additional capital, concentration in development-stage companies, inflation and supply-chain disruption, regulatory and RIC/BDC qualification requirements, and the ability to fund unfunded commitments.
- Subsequent to quarter-end, the company issued 526,581 shares for approximately $5.8 million of net proceeds, received $4.7 million of principal and $0.3 million of ETP payments from Provivi, funded a $0.5 million equity investment in Better Place Forests, and received a $1.0 million principal repayment from Camp NYC.
Most important facts for an investor to verify
- Reconcile the $0.38 per-share Q1 net investment income with the declared distribution of $0.38 per share and assess the sustainability of distributions.
- Review the four non-accrual investments, particularly Nexii, and compare cost, fair value, collateral, and expected recoveries.
- Assess liquidity after considering $168.2 million of unfunded commitments, restricted cash, facility advance-rate limits, and the Key Facility revolving-period end date of June 22, 2024.
- Verify the maturity and refinancing exposure of $456.0 million of gross borrowings, including the $57.5 million 2026 Notes, $57.5 million 2027 Notes, and $100.0 million of 2022 Asset-Backed Notes.
- Evaluate the effect of floating rates on both portfolio income and borrowing costs, including the company’s stated sensitivity estimates.
- Review valuation assumptions for the $709.9 million of Level 3 investments and the sensitivity of NAV to market yields, probability weightings, equity values, and recoveries.
- Monitor the $13.1 million contingent incentive-fee liability and the impact of future equity issuance on NAV per share and shareholder dilution.